Ten-Patient Case Study Series Across an Integrated Care Board

Ten Patient Case Study Series: Across an Integrated Care Board with a Novel New Advanced Wound Dressing with Bioactive Microfibre Gelling (BMG™) Technology Leading to Formulary Application

The wound, initially measuring 10 cm × 5.2 cm, reduced to 7.5 cm × 3 cm by 15th November and was fully healed by 3rd January 2023
Pain scores dropped from 8 to 1 on the Visual Analogue Scale (VAS)

Exceptional exudate control, leading to reduced nursing time from three times a week to weekly dressing changes
Early and effective debridement facilitated, removing 100% biofilm presence

MaxioCel demonstrated superior wound healing benefits, particularly in chronic venous ulcers.
MaxioCel’s ability to rapidly manage exudate and biofilm translated into fewer dressing changes, less healthcare burden, and better patient compliance.
Pain management improvements played a crucial role in patient adherence, with some able to transition to compression therapy—a critical component in venous ulcer care.
Economic benefits include reduced treatment time, lower antibiotic usage, and fewer clinical interventions, supporting formulary inclusion.

Evaluation of a 100% Chitosan Dressing in the Treatment of Diabetic Foot Ulcers

Chronic Wound Debridement in an Acute Setting

Severe Pressure Ulcer Debridement in the Acute Sector

A Multi-disciplinary Team Approach to the Management